CD6 and breast carcinoma: Two other proprietary monoclonal antibodies, the 14F7 anti-ganglioside antibody [44] for breast cancer and the anti-CD6 antibody (itolizumab) for autoimmune diseases [45], together with two new therapeutic vaccines, the N-glycoylganglioside vaccine for breast cancer [46] and the racotumumab anti-idiotype antibody for lung cancer, are currently in clinical testing [47].